Future concepts in the medical therapy of benign prostatic hyperplasia

Current Opinion in Urology

Volumn 11, Issue 1, 2001, Pages 27-33

  Cuellar, David C ^a   Kyprianou, Natasha ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN PLUM; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CEREAL EXTRACT; CUCURBITA PEPO EXTRACT; DOXAZOSIN; ECHINACEA PURPUREA EXTRACT; FINASTERIDE; HIPOXIS REOPERI EXTRACT; PHENOXYBENZAMINE; PLANT EXTRACT; PRAZOSIN; PUMPKIN EXTRACT; PURPLE CONE FLOWER EXTRACT; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SECALE CEREALE EXTRACT; SOUTH AFRICAN STAR GRASS EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; STINGING NEETTLE EXTRACT; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANOREXIA; APOPTOSIS; CLINICAL TRIAL; DRUG EFFICACY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PATHOPHYSIOLOGY; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; APOPTOSIS; FORECASTING; HUMANS; MALE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0035156598     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200101000-00004     Document Type: Review

References (39)

1. Longitudinal changes in peak urinary flow rates in a community based cohort
2. Tissue proliferation: Differential effects of adrenergic agents
3. Role of estrogens in human benign prostatic hyperplasia
4. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperpiasia
5. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy
6. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia
7. Medical management of BPH
8. The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs Cooperative Study
9. Medical therapy for benign prostatic hyperplasia: A review of the literature
10. Safety, efficacy, and impact on patients' quality of life of a long-term treatment with the alpha(1)-biocker alfuzosin in symptomatic patients with BPH
11. Safety and efficacy of sustained-release alfuzosin on dower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3095 Spanish patients evaluated during general practice
12. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg. once daily versus alfuzosin 2.5 mg thrice dairy and placebo in patients with symptomatic benign prostatic hyperplasia
13. Area density of smooth muscle cells and response to endothelin 1 in human hyperplastic prostate
14. Dihydrotestosterone and the concept of 5 alpha-reductase inhibiton in human benign prostatic hyperplasia
15. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes
16. Treatment of benign prostatic hyperplasia
17. Phytotherapy for the prostate
18. Phytotherapy in the treatment of benign prostatic hyperplasia: An update
19. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia
20. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: A randomized international study of 1098 patients
21. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia
22. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review
23. Saw palmetto for the treatment of men with lower urinary tract symptoms
24. Human prostatic steroid 5 alpha-reductase isoforms, A comparative study of selective inhibitors
25. Serenoa repens (Permixon): A 5 alphareductase types I and II inhibitor-new evidence in a coculture model of BPH
26. Effects of long term treatment with Serenoa repens (Permixon) on the concentration and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia
27. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate
28. Effects of saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia
29. Adverse effects of alpha1-adrenergic blocking drugs
30. Induction of prostate apoptosis by doxazosin
31. Alpha1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
32. Induction of apoptosis in the prostate by α1adrenoceptor antagonists: A novel effect of 'old' drugs
33. Transforming growth factor-b1 transduced mouse prostate reconstitutions: Induction of prostate apoptosis by doxazosin
34. Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis
35. Evidence for atrophy and apoptosis in the prostates of men given finasteride
36. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
37. Apoptosis induction in BPH-derived smooth muscle cells: Preclinical studies of a novel gene therapeutic approach to BPH
38. Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7